TOP
Company
Science
News
Career
Contact
EN
JP
We envision a world where we feel tomorrow is another day.
News
2022 / 12 /12
Announces Interim Results of CLK Inhibitor CTX-712 and MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting.
2022 / 11 /21
Published 5th financial report
2022 / 10 /03
Chordia Therapeutics Director and Statutory Auditor Appointments
Learn more
Science
Science
Development Pipelines
CLK
MALT1
CDK12
GCN2
Learn more
Company
Corporate Name
Chordia Therapeutics Inc.
Foundation
November 1, 2017
Head Office
26-1, Muraoka-Higashi 2-chome,
Fujisawa, Kanagawa 251-0012 Japan
Tokyo Office
3-11-5,Nihonbashi-honcho,
Chuo-ku,Tokyo 103-0023 Japan
Representative
Hiroshi Miyake, Ph.D. CEO
Mission
Message
Leadership
Team
Career
People
Recruit
Learn more